Comparison of Elonide and Nasonex nasal spray for the treatment of perennial allergic rhinitis

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

TCTR

Registry ID

TCTR20180828010

Enrollment

Registered

2018-08-28

Start date

2018-09-17

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Perennial Allergic Rhinitis&#44

Interventions

50 mcg/puff&#44

use 2 puffs per nostril once daily from day 1 to day 35 continuously. (Arm 1 are randomized to experimental drug (Elonide NS as generic drug),50 mcg/puff&#44

use 2 puffs per nostril once daily from day 1 to day 35 continuously. (Arm 2 are randomized to active comparator drug (Nasonex NS as innovator drug)

Experimental Drug,Active Comparator Drug

Mometasone furoate nasal spray (generic),Mometasone furoate nasal spray (innovator)

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Moderate to severe symptoms with history nasal allergy at least 12 months, 2 or more symptoms: rhinorrhea, sneezing, itching, nasal obstruction, confirmed by skin prick test positive with a wheal diameter 3 mm to indoor allergen (mite, cockroach, mold)

Exclusion criteria

Exclusion criteria: Pregnancy, Upper and lower respiratory tract infection in 2 weeks prior to the study, Other nasal conditions causing nasal obstruction such as severe deviated nasal septum, nasal polyp, Using intranasal or oral steroids within 4 weeks before first visit, Using antihistamine, antileukotrienes within 2 weeks before first visit, Using decongestant within 1 day before first visit

Design outcomes

Primary

Measure	Time frame
Non-inferior efficacy of Elonide nasal spray and Nasonex nasal spray 5 weeks Total nasal symptom score (TNSS),Non-inferior efficacy of Elonide nasal spray and Nasonex nasal spray 5 weeks Anterior rhinomanometry and Acousticrhinometry	—

Secondary

Measure	Time frame
Incidence of Adverse Events (AE) baseline, Wk1, Wk3, Wk5 AE Report Form follow through TH-FDA guideline	—

Countries

Thailand

Contacts

Public ContactSukhumarn Chaisawat

Faculty of Medicine, Chulalongkorn University

skmuey168@gmail.com0954615932

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026